Efficacy and Safety of Liraglutide in Adolescents Aged 12–15 Years with Obesity: a Prospective 24-week Observational

Background. The problem of childhood obesity remains relevant for modern healthcare. Effective treatment models for this disease are needed with the inclusion of new therapeutic agents, including GLP-1 receptor agonists such as liraglutide (approved from the age of 12). However, its safety and efficacy in pediatrics have not yet been sufficiently studied and require further research. The aim of the study is to evaluate the efficacy and safety of the GLP-1 receptor agonist liraglutide, a solution for subcutaneous administration in pediatric practice for body weight correction in children with obesity aged 12–15 years in combination with a personalized diet and increased physical activity. Methods. The cohort study conducted on the basis of Children’s City Hospital No. 11 (Yekaterinburg) from March to October 2024 included children aged 12–15 years with an exogenously constitutional form of obesity (SDS BMI ≥ 2.0) with confirmed ineffectiveness of lifestyle correction for more than a year. The follow-up period was 24 weeks and included 9 visits. The main criterion of effectiveness is the change in SDS BMI by the 24th week. Safety was assessed by the frequency and severity of adverse events, as well as by the effect on linear growth. Results. The children of the study groups were comparable in all characteristics (p > 0.05). The main group was prescribed liraglutide — an analog of GLP-1— at a dose of 3.0 mg subcutaneously daily. During the first month, the dose was titrated to the maximum according to the instructions, then the drug was used for another 20 weeks. At week 24, a significant decrease in SDS BMI was recorded in the main group compared with the control (therapeutic effect): –0.343 (95% CI: –0.501 to –0.185), p < 0.001. Conclusion. The results obtained confirm the potential of usage of the liraglutide as part of complex therapy in adolescents with obesity and substantiate the expediency of its further study in pediatric practice.

Authors

Institutions

Publication Details

Journal
Педиатрическая фармакология
Published
2025-05-23
DOI
https://doi.org/10.15690/pf.v22i2.2871
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and Safety of Liraglutide in Adolescents Aged 12–15 Years with Obesity: a Prospective 24-week Observational

Margarita Ustiuzhanina, L Kovalchuk, K. Ya. Zaslavskaya, С. И. Солодушкин et al.
Педиатрическая фармакология
Diabetes Treatment and Management
article

Efficacy and Safety of Liraglutide in Adolescents Aged 12–15 Years with Obesity: a Prospective 24-week Observational

Margarita Ustiuzhanina, L Kovalchuk, K. Ya. Zaslavskaya, С. И. Солодушкин, О. П. Ковтун
article en

Abstract

Background. The problem of childhood obesity remains relevant for modern healthcare. Effective treatment models for this disease are needed with the inclusion of new therapeutic agents, including GLP-1 receptor agonists such as liraglutide (approved from the age of 12). However, its safety and efficacy in pediatrics have not yet been sufficiently studied and require further research. The aim of the study is to evaluate the efficacy and safety of the GLP-1 receptor agonist liraglutide, a solution for subcutaneous administration in pediatric practice for body weight correction in children with obesity aged 12–15 years in combination with a personalized diet and increased physical activity. Methods. The cohort study conducted on the basis of Children’s City Hospital No. 11 (Yekaterinburg) from March to October 2024 included children aged 12–15 years with an exogenously constitutional form of obesity (SDS BMI ≥ 2.0) with confirmed ineffectiveness of lifestyle correction for more than a year. The follow-up period was 24 weeks and included 9 visits. The main criterion of effectiveness is the change in SDS BMI by the 24th week. Safety was assessed by the frequency and severity of adverse events, as well as by the effect on linear growth. Results. The children of the study groups were comparable in all characteristics (p > 0.05). The main group was prescribed liraglutide — an analog of GLP-1— at a dose of 3.0 mg subcutaneously daily. During the first month, the dose was titrated to the maximum according to the instructions, then the drug was used for another 20 weeks. At week 24, a significant decrease in SDS BMI was recorded in the main group compared with the control (therapeutic effect): –0.343 (95% CI: –0.501 to –0.185), p < 0.001. Conclusion. The results obtained confirm the potential of usage of the liraglutide as part of complex therapy in adolescents with obesity and substantiate the expediency of its further study in pediatric practice.

Педиатрическая фармакологияVol. 22(2)
Ural Federal University (RU), National Research Mordovia State University (RU), Ural State Medical University (RU), Promore Pharma (Sweden) (SE)
Openalex Percentile: Top 83%
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.